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Abstract
Naxos disease is a recessively inherited condition with arrhythmogenic right ventricular dysplasia/
cardiomyopathy (ARVD/C) and a cutaneous phenotype, characterised by peculiar woolly hair and
palmoplantar keratoderma. The disease was first described in families originating from the Greek
island of Naxos. Moreover, affected families have been identified in other Aegean islands, Turkey,
Israel and Saudi Arabia. A syndrome with the same cutaneous phenotype and predominantly left
ventricular involvement has been described in families from India and Ecuador (Carvajal syndrome).
Woolly hair appears from birth, palmoplantar keratoderma develop during the first year of life and
cardiomyopathy is clinically manifested by adolescence with 100% penetrance. Patients present
with syncope, sustained ventricular tachycardia or sudden death. Symptoms of right heart failure
appear during the end stages of the disease. In the Carvajal variant the cardiomyopathy is clinically
manifested during childhood leading more frequently to heart failure. Mutations in the genes
encoding the desmosomal proteins plakoglobin and desmoplakin have been identified as the cause
of Naxos disease. Defects in the linking sites of these proteins can interrupt the contiguous chain
of cell adhesion, particularly under conditions of increased mechanical stress or stretch, leading to
cell death, progressive loss of myocardium and fibro-fatty replacement. Implantation of an
automatic cardioverter defibrillator is indicated for prevention of sudden cardiac death.
Antiarrhythmic drugs are used for preventing recurrences of episodes of sustained ventricular
tachycardia and classical pharmacological treatment for congestive heart failure, while heart
transplantation is considered at the end stages.
Alternative names of the disease
Naxos syndrome
Associated diseases
Arrhythmogenic right ventricular dysplasia





Naxos disease is a recessively inherited stereotype associa-
tion of arrhythmogenic cardiomyopathy with a cutaneous
phenotype, characterised by peculiar woolly hair and pal-
moplantar keratoderma [1]. Clinical and histological
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studies that compared Naxos disease with arrhyth-
mogenic right ventricular dysplasia/cardiomyopathy
(ARVD/C) showed that the heart disorder was identical in
both diseases [2-4]. Since 1995, according to the classifi-
cation of World Health Organisation, Naxos disease has
been considered as the recessive form of ARVD/C [5].
Epidemiology
The disease was first described by Protonotarios et al in
families originating from the Greek island of Naxos [1].
Apart from Naxos, affected families have been detected in
other Greek Aegean islands, Turkey, Israel and Saudi Ara-
bia [6-9]. The prevalence of the disease in the Greek
islands may be as high as 1:1000. A variety of Naxos dis-
ease, reported as Carvajal syndrome [6], has been
described in families from India and Ecuador [10,11]. It
clinically presents at younger age with predominantly left
ventricular involvement leading to early heart failure and
exhibits a clinical phenotype similar to that of dilated car-
diomyopathy [11,12].
Clinical description
Woolly hair appears from birth, whereas palmoplantar
keratoderma develop during the first year of life when
infants start to use their hands and feet (Figure 1) [13].
The cardiomyopathy clinically manifests by adolescence
and shows 100% penetrance [14]. The symptomatic pres-
entation is usually with syncope and/or sustained ven-
tricular tachycardia of left bundle branch block
configuration (Figure 2). Sudden death may be the first
manifestation of the disease. One third of patients
become symptomatic before the thirtieth year of life. In
some cases, a few clinical findings of an early heart disease
can be detected during childhood.
All patients exhibit repolarisation and/or depolarisation
abnormalities on resting electrocardiogram and struc-
tural/functional abnormalities of the right ventricle on
two-dimensional echocardiography leading to the diag-
nosis of ARVC according to established criteria [15]. Car-
diac histology reveals the characteristic loss of right
ventricular myocardium, mainly in the subepicardial and
mediomural layers with fibro-fatty replacement (Figure 3)
[6,14].
During a mean follow-up period of 10 years, more than
50% of patients develop progressive heart disease involv-
ing the right or both ventricles [14]. The progression
Cutaneous phenotype of Naxos disease: woolly hair (A), palmar (B) and plantar (C) keratoses Figure 1
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appears to be stepwise, associated in some cases with an
arrhythmic storm or sudden death [16]. Symptoms of
right heart failure appear in the final stages when the right
or both ventricles are severely affected. In Carvajal syn-
drome the heart disease is clinically manifested earlier
during childhood as dilated cardiomyopathy [10,11].
Fifty percent of patients developed heart failure and most
of them died during adolescence. Cardiac pathology of a
single case revealed (on gross examination) aneurysms of
the outflow tract, apex and posterior wall of the right ven-
tricle at the "triangle of dysplasia", and involvement of the
left ventricle. Histology showed areas of extensive myocar-
dial loss and replacement fibrosis, particularly in subepi-
cardial layers, that is very similar to ARVD/C pathology
although without the fatty component of replacement
process [17].
Naxos ARVD/C is a rather progressive heart disease with
adverse prognosis, especially in the young. The annual
disease-related and sudden death mortality have been
estimated at 3% and 2.3% respectively [14]. In a long-
term study of an unselected population of patients with
Naxos disease it was shown that risk factors for sudden
death included history of syncope, the appearance of
symptoms and severely progressed disease to the right
ventricle before the age of 35 years, and the involvement
of the left ventricle [14].
Aetiology/Genetics
A two base-pair deletion in the plakoglobin (cell adhesion
protein) gene (Pk2157del2TG), which maps to17q21, has
been identified as the cause of Naxos disease and pro-
vided evidence that the pathogenesis of ARVD/C might be
related to a defect in myocardial mechanical coupling
[13,18]. This mutation was identified in 13 families from
Greece and in one family from Turkey [6]. The prevalence
of heterozygous carriers is up to 5% of the Naxos popula-
tion. Apart from a small minority who show woolly hair,
as well as a few electrocardiographic or echocardiographic
abnormalities not fulfilling the criteria for ARVD/C, heter-
ozygotes dysplay normal phenotype [14]. In the Naxos
disease variety described in families from Ecuador and
Israel (Arab families), two different mutations of the
desmoplakin gene (Dsp7901del1G  and  DspG2375R),
affecting the C-terminal of the protein, have been found
as causative genes [19,20].
Haematoxylin-eosin stained section from the right ventricu- lar free wall of a patient with Naxos disease (surgical sample) Figure 3
Haematoxylin-eosin stained section from the right ventricu-
lar free wall of a patient with Naxos disease (surgical sample). 
There is extensive myocyte loss with fibrofatty replacement 
(magnification × 100).
Spontaneous sustained ventricular tachycardia originating from the right ventricular posterior wall, showing left bundle branch  block configuration and superior axis Figure 2
Spontaneous sustained ventricular tachycardia originating from the right ventricular posterior wall, showing left bundle branch 
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Myocardial cells are differentiated bipolar cells mechani-
cally and electrically coupled at intercalated discs [21].
Adherence junctions and desmosomes secure mechanical
coupling, while gap junctions are involved in electrical
coupling [22]. Plakoglobin (γ-catenin) and desmoplakin
are intracellular proteins anchoring desmosomes to
desmin intermediate filaments. Moreover, plakoglobin
contributes to interlinking adherens junctions with the
actin cytoskeleton, showing also signalling roles to the
nucleus and to desmosome organisation [23,24]. It is also
involved in mechanisms of apoptosis [25]. Defects in
linking sites of these proteins can interrupt the contiguous
chain of cell adhesion, particularly under conditions of
increased mechanical stress or stretch, leading to cell
death, progressive loss of myocardium and fibro-fatty
replacement [18]. The degree of participation of fat in the
repair process may be related to the rate of disease pro-
gression or may be mutation-specific [6]. Surviving myo-
cardial fibres within fibro-fatty tissue form zones of slow
conduction and provide a substrate for re-entry ventricu-
lar arrhythmias [26]. Recent studies on Naxos disease
myocardium revealed that remodelling of gap junctions
and altered electrical coupling might be an early result of
the genetically determined defect in cell adhesion,
enhancing the development of a highly arrhythmogenic
substrate [27].
Treatment and prevention
The primary goal is the prevention of sudden cardiac
death. Implantation of an automatic cardioverter defibril-
lator is indicated in patients who develop symptoms and/
or structural progression, particularly before the age of 35
years [14,28,29]. Antiarrhythmic drugs are indicated for
preventing recurrences of episodes of sustained ventricu-
lar tachycardia; sotalol and amiodarone, either alone or in
combination with classical β-blockers, seem to be the
most effective [26,30]. Patients with congestive heart fail-
ure are managed with diuretics and angiotensin-convert-
ing enzyme (ACE) inhibitors, while heart transplantation
is considered at the end stages.
In an attempt to control Naxos disease, systematic genetic
screening of the populations at risk has been initiated and
is starting to identify the heterozygous carriers of the pla-
koglobin gene mutation.
A multicentre European study is under way aiming to
determine the clinical, pathological and genetic character-
istics of ARVD/C, validate the diagnostic criteria and
define strategies for disease treatment and prevention of
sudden death http://anpat.unipd.it/ARVC/[31]. One of
the missions is the study of Naxos disease (participating
unit: Yannis Protonotarios Medical Center, Naxos).
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